lonaprisan

12/28/2000 - "In tumor models ZK 230211 exhibited strong antiproliferative action. "
05/26/2010 - "Induction of cell death by anti-hormones such as ICI182780 and ZK230211 was more effective in MPA-dependent tumors with lower AKT activity. "
03/01/2010 - "In summary, our studies demonstrate ZK 230211 to be a type III progesterone receptor antagonist which is characterized by very strong DNA binding activity and strong antiproliferative effects in the cancer cell lines HeLa and T47D."

02/10/2011 - "Here we studied the effects of the new antiprogestin Lonaprisan on the T47D breast cancer cell line. "
02/10/2011 - "The antiprogestin Lonaprisan inhibits breast cancer cell proliferation by inducing p21 expression."
10/01/2013 - "This randomized, open-label, phase II study evaluated the efficacy and tolerability of lonaprisan as second-line endocrine therapy in postmenopausal women with stage IV, PR-positive, HER2-negative, metastatic breast cancer. "
10/01/2013 - "Lonaprisan showed limited efficacy as second-line endocrine therapy in postmenopausal women with PR-positive metastatic breast cancer."
10/01/2013 - "Randomized phase II study of lonaprisan as second-line therapy for progesterone receptor-positive breast cancer."

12/28/2000 - "The pharmacological properties of ZK 230211 may prove useful in the treatment of endometriosis, leiomyomas, breast cancer, and in hormone replacement therapy."

12/28/2000 - "The pharmacological properties of ZK 230211 may prove useful in the treatment of endometriosis, leiomyomas, breast cancer, and in hormone replacement therapy."

09/01/2007 - "Short-term intrauterine release of ZK230211 did not change bleeding patterns or result in endometrial suppression. "
09/01/2007 - "Bleeding patterns, endometrial morphology and content of ZK230211, and various immunohistochemistries (IHCs) were evaluated. "